Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis.

Spiegel DY, Boyer MJ, Hong JC, Williams CD, Kelley MJ, Salama JK, Palta M.

J Natl Compr Canc Netw. 2020 Jan;18(1):52-58. doi: 10.6004/jnccn.2019.7329.

PMID:
31910388
2.

Molecular dynamics investigation of reduced ethylene carbonate aggregation at the onset of solid electrolyte interphase formation.

Boyer MJ, Hwang GS.

Phys Chem Chem Phys. 2019 Oct 28;21(40):22449-22455. doi: 10.1039/c9cp04316k. Epub 2019 Oct 3.

PMID:
31580348
3.

Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry.

Hong JC, Boyer MJ, Spiegel DY, Williams CD, Tong BC, Shofer SL, Moravan MJ, Kelley MJ, Salama JK.

J Natl Compr Canc Netw. 2019 Feb;17(2):127-139. doi: 10.6004/jnccn.2018.7090.

PMID:
30787126
4.

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y.

Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.

PMID:
30659024
5.

A cytoskeletal anchor connects ischemic mitochondrial fission to myocardial senescence.

Boyer MJ, Eguchi S.

Sci Signal. 2018 Nov 13;11(556). pii: eaav3267. doi: 10.1126/scisignal.aav3267. Review.

PMID:
30425163
6.

Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration.

Spiegel DY, Boyer MJ, Hong JC, Williams CD, Kelley MJ, Moore H, Salama JK, Palta M.

Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):565-573. doi: 10.1016/j.ijrobp.2018.10.018. Epub 2018 Oct 22.

PMID:
30359718
7.

Novel role for cardiac myocyte-derived β-2 microglobulin in mediating cardiac fibrosis.

Boyer MJ, Eguchi S.

Clin Sci (Lond). 2018 Oct 5;132(19):2117-2120. doi: 10.1042/CS20180681. Print 2018 Oct 15.

PMID:
30291210
8.

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.

Barnet MB, Cooper WA, Boyer MJ, Kao S.

J Clin Med. 2018 Jun 14;7(6). pii: E151. doi: 10.3390/jcm7060151. Review.

9.

Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes.

Barnet MB, Blinman P, Cooper W, Boyer MJ, Kao S, Goodnow CC.

Bioessays. 2018 Aug;40(8):e1800050. doi: 10.1002/bies.201800050. Epub 2018 Jun 4. Review.

PMID:
29869436
10.

Somatic mutations in salivary duct carcinoma and potential therapeutic targets.

Khoo TK, Yu B, Smith JA, Clarke AJ, Luk PP, Selinger CI, Mahon KL, Kraitsek S, Palme C, Boyer MJ, Dinger ME, Cowley MJ, O'Toole SA, Clark JR, Gupta R.

Oncotarget. 2017 May 25;8(44):75893-75903. doi: 10.18632/oncotarget.18173. eCollection 2017 Sep 29.

11.

Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.

Boyer MJ, Williams CD, Harpole DH, Onaitis MW, Kelley MJ, Salama JK.

J Thorac Oncol. 2017 Dec;12(12):1814-1823. doi: 10.1016/j.jtho.2017.09.1952. Epub 2017 Sep 23.

12.

Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/β-Aminopropionitrile-Induced Abdominal Aortic Aneurysm.

Kawai T, Takayanagi T, Forrester SJ, Preston KJ, Obama T, Tsuji T, Kobayashi T, Boyer MJ, Cooper HA, Kwok HF, Hashimoto T, Scalia R, Rizzo V, Eguchi S.

Hypertension. 2017 Nov;70(5):959-963. doi: 10.1161/HYPERTENSIONAHA.117.09822. Epub 2017 Sep 25.

13.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.

Lancet Oncol. 2017 Oct;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6. Epub 2017 Sep 1.

PMID:
28870611
14.

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.

J Thorac Oncol. 2017 Sep;12(9):1421-1433. doi: 10.1016/j.jtho.2017.05.024. Epub 2017 Jun 16. Erratum in: J Thorac Oncol. 2018 Apr;13(4):587.

15.

Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial.

Dhillon HM, Bell ML, van der Ploeg HP, Turner JD, Kabourakis M, Spencer L, Lewis C, Hui R, Blinman P, Clarke SJ, Boyer MJ, Vardy JL.

Ann Oncol. 2017 Aug 1;28(8):1889-1897. doi: 10.1093/annonc/mdx205.

16.

Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.

Boyer MJ, Papagikos MA, Kiteley R, Vujaskovic Z, Wu J, Lee WR.

Radiat Oncol. 2017 Jan 13;12(1):14. doi: 10.1186/s13014-016-0758-8.

17.

Caveolin-1 Deletion Prevents Hypertensive Vascular Remodeling Induced by Angiotensin II.

Forrester SJ, Elliott KJ, Kawai T, Obama T, Boyer MJ, Preston KJ, Yan Z, Eguchi S, Rizzo V.

Hypertension. 2017 Jan;69(1):79-86. Epub 2016 Nov 28.

18.

Structure and Li+ ion transport in a mixed carbonate/LiPF6 electrolyte near graphite electrode surfaces: a molecular dynamics study.

Boyer MJ, Vilčiauskas L, Hwang GS.

Phys Chem Chem Phys. 2016 Oct 12;18(40):27868-27876.

PMID:
27711674
19.

Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.

Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, Dunphy FR, Crawford J, Ready NE, Salama JK.

Lung Cancer. 2016 Aug;98:76-78. doi: 10.1016/j.lungcan.2016.05.014. Epub 2016 May 25.

PMID:
27393510
20.

Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Kao SC, Boyer MJ.

J Clin Oncol. 2016 Sep 20;34(27):3233-4. doi: 10.1200/JCO.2016.66.9952. Epub 2016 Apr 11. No abstract available.

PMID:
27069076
21.

Ablative Approaches for Pulmonary Metastases.

Boyer MJ, Ricardi U, Ball D, Salama JK.

Thorac Surg Clin. 2016 Feb;26(1):19-34. doi: 10.1016/j.thorsurg.2015.09.004. Review.

PMID:
26611507
22.

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.

Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG.

Br J Cancer. 2015 Apr 14;112(8):1340-8. doi: 10.1038/bjc.2015.74. Epub 2015 Mar 31.

23.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L.

Lancet Oncol. 2014 Nov;15(12):1369-78. doi: 10.1016/S1470-2045(14)70452-8. Epub 2014 Oct 15.

PMID:
25439691
24.

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.

Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G, Gurney H, Mallesara G, Molloy PL, Horvath LG, Clark SJ; PRIMe consortium.

Br J Cancer. 2014 Oct 28;111(9):1802-9. doi: 10.1038/bjc.2014.463. Epub 2014 Aug 21.

25.

Palliative radiotherapy for prostate cancer.

Boyer MJ, Salama JK, Lee WR.

Oncology (Williston Park). 2014 Apr;28(4):306-12. Review.

26.

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.

Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, Horvath LG.

Br J Cancer. 2014 May 13;110(10):2462-71. doi: 10.1038/bjc.2014.181. Epub 2014 Apr 8.

27.

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA.

Eur J Cancer. 2014 Mar;50(4):706-12. doi: 10.1016/j.ejca.2013.11.032. Epub 2013 Dec 17.

PMID:
24360368
28.

Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.

Yip PY, Cooper WA, Kohonen-Corish MR, Lin BP, McCaughan BC, Boyer MJ, Kench JG, Horvath LG.

J Clin Pathol. 2014 Apr;67(4):333-40. doi: 10.1136/jclinpath-2013-201870. Epub 2013 Nov 21.

PMID:
24265323
29.

Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.

Yip PY, Yu B, Cooper WA, Selinger CI, Ng CC, Kennedy CW, Kohonen-Corish MR, McCaughan BC, Trent RJ, Boyer MJ, Kench JG, Horvath LG, O'Toole SA.

J Thorac Oncol. 2013 Apr;8(4):408-14. doi: 10.1097/JTO.0b013e318283558e.

30.

Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer.

McCaughan GJ, Blinman PL, Boyer MJ, Stockler MR.

Intern Med J. 2013 Apr;43(4):424-9. doi: 10.1111/j.1445-5994.2012.02846.x.

PMID:
22647141
31.

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ.

Clin Cancer Res. 2010 Dec 1;16(23):5805-13. doi: 10.1158/1078-0432.CCR-10-2245. Epub 2010 Oct 18.

32.

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.

Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC.

J Natl Cancer Inst. 2010 Aug 18;102(16):1253-62. doi: 10.1093/jnci/djq245. Epub 2010 Jul 14.

PMID:
20631341
33.

A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.

Moore MM, Stockler M, Lim R, Mok TS, Millward M, Boyer MJ.

Cancer Chemother Pharmacol. 2010 Oct;66(5):845-50. doi: 10.1007/s00280-009-1228-x. Epub 2010 Jan 16.

PMID:
20082080
34.

ADAR1 is required for hematopoietic progenitor cell survival via RNA editing.

XuFeng R, Boyer MJ, Shen H, Li Y, Yu H, Gao Y, Yang Q, Wang Q, Cheng T.

Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17763-8. doi: 10.1073/pnas.0903324106. Epub 2009 Oct 2.

35.

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG.

Cancer Res. 2009 Oct 1;69(19):7696-703. doi: 10.1158/0008-5472.CAN-08-4901. Epub 2009 Sep 22.

36.

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chui W, Lee JS.

J Clin Oncol. 2009 Oct 20;27(30):5080-7. doi: 10.1200/JCO.2008.21.5541. Epub 2009 Sep 8.

PMID:
19738125
37.

An elusive tumor in a man who has evidence of prostate cancer metastasis.

Boyer BP, Boyer MJ.

JAAPA. 2009 Aug;22(8):22, 24-5. No abstract available.

PMID:
19725410
38.

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

Soon YY, Stockler MR, Askie LM, Boyer MJ.

J Clin Oncol. 2009 Jul 10;27(20):3277-83. doi: 10.1200/JCO.2008.19.4522. Epub 2009 May 26. Review.

PMID:
19470938
39.

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.

Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC.

Am J Clin Oncol. 2009 Aug;32(4):338-41. doi: 10.1097/COC.0b013e31818b946b.

PMID:
19363437
40.

Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer.

Martin RC, Fulham M, Shannon KF, Hughes C, Gao K, Milross C, Tin MM, Jackson M, Clifford A, Boyer MJ, O'Brien CJ.

Head Neck. 2009 Feb;31(2):244-50. doi: 10.1002/hed.20962.

PMID:
19073005
41.

Quality of life and survival in the 2 years after surgery for non small-cell lung cancer.

Kenny PM, King MT, Viney RC, Boyer MJ, Pollicino CA, McLean JM, Fulham MJ, McCaughan BC.

J Clin Oncol. 2008 Jan 10;26(2):233-41. Epub 2007 Dec 17.

PMID:
18086802
42.

The CDK inhibitors: potential targets for therapeutic stem cell manipulations?

Boyer MJ, Cheng T.

Gene Ther. 2008 Jan;15(2):117-25. Epub 2007 Nov 8. Review.

PMID:
17989702
43.

Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer.

Stockler MR, Tattersall MH, Boyer MJ, Clarke SJ, Beale PJ, Simes RJ.

Br J Cancer. 2006 Jan 30;94(2):208-12.

44.

Hematopoietic stem cells are not the direct target of spontaneous leukemic transformation in p18(INK4C)-null reconstituted mice.

Yuan Y, Yu H, Boyer MJ, Song X, Cao S, Shen H, Cheng T.

Cancer Res. 2006 Jan 1;66(1):343-51.

45.

Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.

Joshua AM, Nordman I, Venkataswaran R, Clarke S, Stockler MR, Boyer MJ.

Intern Med J. 2005 Aug;35(8):468-72.

PMID:
16176469
46.

A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.

Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D, White S, Childs A, Beale P, Latz J, Suri A, Iglesias JL.

Lung Cancer. 2005 Sep;49(3):401-12.

PMID:
15923057
47.
48.

Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer.

Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, McCaughan BC, Fulham MJ.

J Clin Oncol. 2004 Jun 15;22(12):2357-62.

PMID:
15197196
49.

Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma.

Joshua AM, Stockler MR, Boyer MJ.

Intern Med J. 2004 Jan-Feb;34(1-2):70-1. No abstract available.

PMID:
14748919
50.

Human arteries engineered in vitro.

McKee JA, Banik SS, Boyer MJ, Hamad NM, Lawson JH, Niklason LE, Counter CM.

EMBO Rep. 2003 Jun;4(6):633-8.

Supplemental Content

Loading ...
Support Center